Innovation
Ahead of disease
Innovation is at the heart of achieving our purpose – to unite science, technology and talent to get ahead of disease together.
How our R&D approach helps us get Ahead Together
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We are also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
-
Our R&D investment in 2021
£5.3bn -
An outstanding R&D team of
15k
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of new products that help us to get ahead of disease togetherTherapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.
Advanced technology platforms such as AI, machine learning and functional genomics are central to our R&D approach. At the same time, diverse vaccine platform technologies including the use of adjuvants and mRNA technology have the potential to drive the next generation of vaccines and medicines.
Diseases and medicines can affect people differently depending on their race, ethnicity, sex or age. It’s therefore vital that we represent the real-world disease population in our clinical trials to advance our understanding of new vaccines and medicines, to create better health outcomes for the patients who rely on us.
Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.
Our leading R&D centres in the UK, US, Belgium and Italy are pivotal in helping us to get ahead of disease around the world.
